文献速递肿瘤 PET/CT核素与放射性配体治疗

快速进展复发性嗜铬细胞瘤中的肺淋巴管癌病:一例展示99mTc-FAPI-46与99mTc-HYNIC-奥曲肽扫描对等诊断价值的病例

Pulmonary Lymphangitis Carcinomatosis in Rapid Progressive Recurrent Pheochromocytoma: A Case Exhibiting the Peer Diagnostic Value of 99mTc-FAPI-46 and 99mTc-HYNIC-Octreotide Scans.
PubMed 文献 · Clin Nucl Med · 2025-06-04

43岁女性,左肾上腺嗜铬细胞瘤切除术后2个月疑复发,影像示肺及腹部淋巴结转移,长效奥曲肽治疗后症状加重,转核医学科行诊疗一体化评估,再评估发现左肾上腺床复发及肺、肝、淋巴结、骨骼多发转移;99mTc-FAPI-46显像与99mTc-HYNIC-奥曲肽扫描显示相似的显像能力。

要点

  • 43岁女性左肾上腺嗜铬细胞瘤术后2个月疑复发,影像见肺及腹部淋巴结转移。
  • 长效奥曲肽治疗后症状加重,转核医学科行诊疗一体化评估。
  • 再评估见左肾上腺床复发及肺、肝、淋巴结、骨骼多发转移。

核心结论

  • 99mTc-FAPI-46显像在本例中与99mTc-HYNIC-奥曲肽扫描显示相似的显像能力,突显其在转移性嗜铬细胞瘤显像和治疗中的潜力。

研究设计与样本

  • 病例报告:43岁女性,有左肾上腺嗜铬细胞瘤病史,肾上腺切除术后2个月疑复发。

主要发现

  • 影像评估显示肺和腹部淋巴结转移性病灶。
  • 尽管初始使用长效奥曲肽治疗,患者症状仍加重。
  • 综合再评估显示左肾上腺床复发肿瘤及肺、肝、淋巴结和骨骼多发转移灶。
  • 99mTc-FAPI-46闪烁显像与99mTc-HYNIC-奥曲肽扫描相比显示相似的显像能力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 43-year-old woman with a history of left adrenal pheochromocytoma was suspected for recurrence 2 months after adrenalectomy. Imaging assessments revealed metastatic lesions in the lungs and abdominal lymph nodes. Despite initial treatment with long-acting octreotide, the patient's symptoms worsened. Consequently, the patient was referred to the nuclear medicine department for theragnostic purposes. Comprehensive re-evaluation revealed a recurrent tumor in the left adrenal bed and multiple metastatic lesions, including lung, liver, lymph nodes, and skeletal metastases. In this patient, 99mTc-FAPI-46 scintigraphy demonstrated similar imaging capabilities compared with 99mTc-HYNIC-Octreotide scan, highlighting its potential in metastatic pheochromocytoma imaging and therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Raeisi N, Saber Tanha A, Aryana K, et al. Pulmonary Lymphangitis Carcinomatosis in Rapid Progressive Recurrent Pheochromocytoma: A Case Exhibiting the Peer Diagnostic Value of 99mTc-FAPI-46 and 99mTc-HYNIC-Octreotide Scans. Clin Nucl Med. 2025. PMID: 40462325. doi:10.1097/RLU.0000000000005710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。